| Literature DB >> 35418765 |
Xinbang Liu1,2, Qiuyue Ren3, Yangkui Zhai1,2, Yihan Kong1,2, Dong Chen4, Bai Chang1,2.
Abstract
Objective: The aim of this study is to analyze the microbiological characteristics of diabetic foot ulcer (DFU) and drug resistance of multidrug-resistant organisms (MDROs) and to reveal the potential risk factors for MDROs. This provides a basis for early empiric antibiotic treatment.Entities:
Keywords: diabetic foot ulcer; infection; logistic regression analysis; multidrug-resistant organisms; risk factors
Year: 2022 PMID: 35418765 PMCID: PMC8999704 DOI: 10.2147/IDR.S359157
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
Baseline Data of Patients with Diabetic Foot Ulcer
| Characteristics | Total (N=348) | MDRM+ (N=202) | MDRM- (N=146) | |
|---|---|---|---|---|
| Age (years) | 63.99±11.40 | 63.74±11.97 | 64.34±10.59 | 0.63 |
| Sex [n (%)] | 0.35 | |||
| Male | 250 (71.8) | 149 (73.8) | 101 (69.2) | |
| Female | 98 (28.2) | 53 (26.2) | 45 (30.8) | |
| Previous hospitalization [n (%)] | <0.01 | |||
| Yes | 177 (50.9) | 122 (60.4) | 55 (37.7) | |
| No | 171 (49.1) | 80 (39.6) | 91 (62.3) | |
| Previous antibiotic therapy [n (%)] | 0.01 | |||
| Yes | 275 (79) | 172 (85.1) | 103 (70.5) | |
| No | 73 (21) | 30 (14.9) | 43 (29.5) | |
| Diabetes duration (years) | 15.0 (9.3,21) | 15.0 (10.0,20.0) | 15.0 (8.0,23.3) | 0.72 |
| Ulcer duration (weeks) | 8.0 (3.0,16.0) | 8.0 (3.0,16.0) | 8.0 (2.0,16.0) | 0.91 |
| Ulcer size>4cm2 [n (%)] | <0.01 | |||
| Yes | 186 (53.4) | 128 (63.4) | 58 (39.7) | |
| No | 162 (46.6) | 74 (36.6) | 88 (60.3) | |
| Osteomyelitis [n (%)] | 0.32 | |||
| Yes | 246 (70.7) | 147 (72.8) | 99 (67.8) | |
| No | 102 (29.3) | 55 (27.2) | 47 (32.2) | |
| Retinopathy [n (%)] | 0.37 | |||
| Yes | 179 (51.4) | 108 (53.5) | 71 (48.6) | |
| No | 169 (48.6) | 94 (46.5) | 75 (51.4) | |
| DKD [n (%)] | 0.11 | |||
| Yes | 182 (52.3) | 113 (55.9) | 69 (47.3) | |
| No | 166 (47.7) | 89 (44.1) | 77 (52.7) | |
| Surgical therapy [n (%)] | <0.01 | |||
| Yes | 59 (17.0) | 47 (23.3) | 12 (8.2) | |
| No | 289 (83.0) | 155 (76.7) | 134 (91.8) | |
| SBP (mmHg) | 137.51±19.58 | 137.61±20.19 | 137.38±18.77 | 0.91 |
| DBP (mmHg) | 77.01±12.16 | 76.82±11.94 | 77.28±12.49 | 0.73 |
| Fibrinogen (g/L) | 5.28±1.88 | 5.41±1.97 | 5.10±1.75 | 0.12 |
| D-Dimer (mg/L) | 0.78 (0.47,1.34) | 0.85 (0.49,1.47) | 0.67 (0.44,1.09) | <0.01 |
| HbA1c (%) | 8.58±2.03 | 8.59±1.91 | 8.56±2.18 | 0.88 |
| TG (mmol/L) | 1.35±0.74 | 1.38±0.77 | 1.32±0.69 | 0.47 |
| TC (mmol/L) | 4.28±1.30 | 4.23±1.28 | 4.35±1.33 | 0.38 |
| LDL-C (mmol/L) | 2.98±1.00 | 2.96±0.98 | 3.02±1.03 | 0.62 |
| CRP (mg/L) | 24.59 (0.50,73.07) | 30.61 (6.33,81.04) | 18.6 (3.61,49.82) | <0.01 |
Logistic Regression Analysis of MDRO Infection in DFU Patients
| Characteristics | Univariable Analysis | Multivariable Analysis | ||||
|---|---|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | |||
| Age | 1.00 | 0.98–1.01 | 0.63 | |||
| Male gender | 0.80 | 0.50–1.29 | 0.35 | |||
| Previous hospitalization | 2.52 | 1.63–3.91 | <0.01 | 1.91 | 1.11–3.28 | 0.02 |
| Previous antibiotic therapy | 2.39 | 1.41–4.05 | <0.01 | 1.17 | 0.63–2.20 | 0.62 |
| Diabetes duration | 1.00 | 0.98–1.02 | 0.98 | |||
| Ulcer duration | 1.00 | 0.99–1.00 | 0.58 | |||
| Ulcer size>4cm2 | 2.62 | 1.69–4.07 | <0.01 | 1.68 | 1.03–2.76 | 0.04 |
| Osteomyelitis | 1.27 | 0.80–2.02 | 0.32 | |||
| Retinopathy | 1.21 | 0.79–1.86 | 0.37 | |||
| DKD | 0.71 | 0.46–1.08 | 0.11 | |||
| Surgical therapy | 3.39 | 1.72–6.65 | <0.01 | 2.14 | 1.03–4.47 | 0.04 |
| SBP | 1.00 | 0.99–1.01 | 0.91 | |||
| DBP | 1.00 | 0.98–1.02 | 0.73 | |||
| Fibrinogen | 1.10 | 0.98–1.23 | 0.12 | |||
| D-Dimer | 1.20 | 1.01–1.42 | 0.04 | 1.09 | 0.92–1.28 | 0.32 |
| HbA1c | 1.01 | 0.91–1.12 | 0.88 | |||
| TG | 1.12 | 0.83–1.50 | 0.47 | |||
| TC | 0.93 | 0.79–1.09 | 0.38 | |||
| LDL-C | 0.95 | 0.77–1.17 | 0.62 | |||
| CRP | 1.01 | 1.00–1.01 | <0.01 | 1.01 | 1.00–1.01 | 0.03 |
Bacterial Distribution and Drug Resistance Rate
| Bacteria | MDRO+ | MDRO- | Resistant Rates |
|---|---|---|---|
| Gram positive | |||
| | |||
| | 21 | 29 | 0.42 |
| | 21 | 2 | 0.91 |
| Other | 8 | 3 | 0.73 |
| | 20 | 24 | 0.45 |
| | 18 | 3 | 0.86 |
| Gram negative | |||
| | 20 | 6 | 0.77 |
| | 8 | 17 | 0.32 |
| | 5 | 8 | 0.38 |
| | 14 | 13 | 0.52 |
| | 5 | 13 | 0.28 |
| | 16 | 31 | 0.34 |
| | 12 | 37 | 0.24 |
| | 5 | ||
| | 33 | 14 | 0.70 |
| Others | 34 | 35 | 0.49 |
| Total | 240 | 235 | 0.51 |
Resistance Rate of Common MDRO to Commonly Used Antibiotics
| Antibiotic | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Strains | Resistance Rates (%) | Strains | Resistance Rates (%) | Strains | Resistance Rates (%) | Strains | Resistance Rates (%) | Strains | Resistance Rates (%) | Strains | Resistance Rates (%) | |
| Oxacillin or cefoxitin | 6 | 28.6 | ||||||||||
| Levofloxacin | 9 | 42.9 | 5 | 41.7 | 30 | 90.9 | 18 | 90.0 | 16 | 100.0 | 7 | 38.9 |
| Moxifloxacin | 8 | 38.1 | 12 | 60.0 | 12 | 75.0 | ||||||
| Penicillin | 21 | 100.0 | 1 | 0.1 | ||||||||
| Vancomycin | 0 | 0.0 | 0 | 0.0 | ||||||||
| Gentamicin | 12 | 57.1 | 2 | 16.7 | 9 | 45.0 | 9 | 56.3 | 9 | 50.0 | ||
| Tobramycin | 0 | 0.0 | 23 | 69.7 | 9 | 45.0 | 8 | 50.0 | ||||
| Erythromycin | 16 | 76.2 | 18 | 100.0 | ||||||||
| Clindamycin | 16 | 76.2 | 18 | 100.0 | ||||||||
| Quinupristin/Dalfopristin | 0 | 0.0 | 17 | 94.4 | ||||||||
| Amoxicillin/Clavulanic acid | 12 | 100.0 | 33 | 100.0 | 6 | 30.0 | 9 | 56.3 | ||||
| Piperacillin/Tazobactam | 6 | 50.0 | 28 | 84.8 | 3 | 15.0 | 8 | 50.0 | ||||
| Meropenem | 4 | 33.3 | 30 | 90.9 | 1 | 5.0 | 0 | 0.0 | ||||
| Imipenem | 3 | 25.0 | 29 | 87.9 | 1 | 5.0 | 1 | 0.1 | ||||
| Ertapenem | 12 | 100.0 | 1 | 5.0 | 0 | 0.0 | ||||||
| Cefazolin | 12 | 100.0 | 20 | 100.0 | 16 | 100.0 | ||||||
| Cefuroxim | 12 | 100.0 | 33 | 100.0 | 15 | 75.0 | 15 | 93.8 | ||||
| Ceftriaxone | 12 | 100.0 | 13 | 65.0 | 9 | 56.3 | ||||||
| Ceftazidime | 4 | 33.3 | 28 | 84.4 | 5 | 25.0 | 3 | 18.8 | ||||
| Cefepime | 3 | 25.0 | 28 | 84.4 | 4 | 20.0 | 1 | 0.1 | ||||
| Tetracycline | 3 | 14.3 | 12 | 100.0 | 26 | 78.8 | 15 | 75.0 | 14 | 87.5 | 17 | 94.4 |
| Aztreonam | 33 | 100.0 | 6 | 30.0 | 5 | 31.3 | ||||||
| Sulfamethoxazole | 13 | 61.9 | 12 | 100.0 | 12 | 36.4 | 11 | 55.0 | 11 | 68.8 | ||
| Polymyxin | 0 | 0.0 | ||||||||||